- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Add on phototherapy to ritlecitinib Boosts Vitiligo Treatment Response and Patient Satisfaction: Study

Researchers have found in an exploratory phase IIb study that adding twice-weekly narrowband UVB phototherapy to oral ritlecitinib (Litfulo) improved repigmentation outcomes in patients with nonsegmental vitiligo compared to ritlecitinib alone. The combination therapy was well-tolerated with no new safety concerns, and patient satisfaction nearly doubled with the dual approach.
Ritlecitinib, an oral selective dual JAK3/TEC family kinase inhibitor, was evaluated for its efficacy and safety in adolescents and adults with alopecia areata in a large, randomized, double-blind, multicentre phase 2b–3 clinical trial. Conducted across 118 sites in 18 countries, the study included patients aged 12 years and older with at least 50% scalp hair loss. Participants were randomly assigned to various dosing regimens of ritlecitinib or placebo over a 24-week treatment period, followed by a 24-week extension during which those initially on placebo were switched to ritlecitinib.
The trial demonstrated that ritlecitinib led to meaningful clinical improvement in hair regrowth as measured by the Severity of Alopecia Tool (SALT) score. The most substantial improvements were observed in the higher-dose treatment groups, and notably, few patients in the placebo group showed any response. The treatment was generally well tolerated, with adverse events reported at similar frequencies across all treatment groups, and no deaths occurred during the study.
These results support the potential of ritlecitinib as an effective and tolerable treatment option for alopecia areata in patients eligible for systemic therapy.
Reference:
King, B., Zhang, X., Harcha, W. G., Szepietowski, J. C., Shapiro, J., Lynde, C., Mesinkovska, N. A., Zwillich, S. H., Napatalung, L., Wajsbrot, D., Fayyad, R., Freyman, A., Mitra, D., Purohit, V., Sinclair, R., & Wolk, R. (2023). Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. The Lancet, 401(10392), 1928. https://doi.org/10.1016/S0140-6736(23)00222-2
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751